Evidence map›Paper›PMID 30510846›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2018

A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer.

Babs G Sibinga Mulder, Henricus Jm Handgraaf, Danielle J Vugts, Claudia Sewing, Albert D Windhorst, Marieke Stammes, Lioe-Fee de Geus-Oei, Mark W Bordo, J Sven D Mieog, Cornelis Jh van de Velde and 2 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Babs G Sibinga MulderDepartment of Surgery, Leiden University Medical Center Leiden, The Netherlands.
Henricus Jm HandgraafDepartment of Surgery, Leiden University Medical Center Leiden, The Netherlands.
Danielle J VugtsDepartment of Nuclear Medicine, VU Medical Center Amsterdam, The Netherlands.
Claudia SewingDepartment of Nuclear Medicine, VU Medical Center Amsterdam, The Netherlands.
Albert D WindhorstDepartment of Nuclear Medicine, VU Medical Center Amsterdam, The Netherlands.
Marieke StammesDepartment of Radiology, Leiden University Medical Center Leiden, The Netherlands.
Lioe-Fee de Geus-OeiDepartment of Nuclear Medicine, Leiden University Medical Center Leiden, The Netherlands.
Mark W BordoCuradel, LLC Marlborough, MA, U.S.A.
J Sven D MieogDepartment of Surgery, Leiden University Medical Center Leiden, The Netherlands.
Cornelis Jh van de VeldeDepartment of Surgery, Leiden University Medical Center Leiden, The Netherlands.
John V FrangioniCuradel, LLC Marlborough, MA, U.S.A.
Alexander L VahrmeijerDepartment of Surgery, Leiden University Medical Center Leiden, The Netherlands.
Leiden University Medical Center · NL

Funding

(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and TreatmentR01CA185457 · NCI · CURADEL, LLC · PI FRANGIONI, JOHN V · 2014 to 2017
$3.9M
European Research Council 323105NCI NIH HHS R01 CA185457
6 · The paper itself

Abstract

cRGD peptides target integrins associated with angiogenesis (e.g., α

Indexed as

colorectal cancercRGDHybrid tracermolecular imagingnear-infrared fluorescence imagingPET imaging

Identifiers

PMID30510846
PMCPMC6261878
OpenAlexW2912209933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.